Browse by Poster Author

Skip to main content

iwCLL 2025 Main banner

iwCLL X / Twitter

Browse by Poster Author

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

N
Nabki, Jana

Università del Piemonte Orientale
1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Jana Nabki
Favorite
1227 - Clinical and Biological Impact of Plasma Cytokine Levels in Newly Diagnosed Chronic Lymphocytic Leukemia
Jana Nabki
Favorite
Nadeu, Ferran

Institut d'Investigacions Biomèdiques August Pi i Sunyer
1101 - An immuno-(epi)genomic classification of chronic lymphocytic leukemia refines outcome prediction
Ferran Nadeu
Favorite
1103 - Identification and multi-omic characterization of a novel molecular subtype of CLL based on EBF1 expression levels
Ferran Nadeu
Favorite
1905 - Academic CD19-directed CAR-T ARI-0001 (varnimcabtagene autoleucel) for patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation
Ferran Nadeu
Favorite
Nagler, Adi

Department of Medical Oncology, Dana-Farber Cancer Institute
1009 - Epigenetic and transcriptional single-cell profiling reveals CLL-like states in low-count MBL
Adi Nagler
Favorite
Nano, Ennio

Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino
1304 - Linking Cytokine Signaling and Metabolism in Chronic Lymphocytic Leukemia: The Translational Relevance of the IL-12 Family
Ennio Nano
Favorite
Napolitani, Giorgio

Department of Haematology, Comprehensive Cancer Centre, King’s College London
1224 - A fraction of lymph node CLL B cells exhibits high expression of T-bet
Giorgio Napolitani
Favorite
Nardi, Federica

Fondazione Toscana Life Sciences
1006 - ApoliproteinE induces ferroptosis in chronic lymphocytic leukaemia cells
Federica Nardi
Favorite
Nasser, Ahlam

Muhimbili University of Health and Allied Science
1102 - Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania.
Ahlam Nasser
Favorite
Navarrete Bullón, Laura

Hospital Universitario de Gran Canaria Dr. Negrín
1109 - Integrating clinical and genomic factors to predict time to first treatment in chronic lymphocytic leukemia
Laura Navarrete Bullón
Favorite
Navarrete, Marcelo

Universidad de Magallanes
1211 - Unraveling a poor-prognosis CLL subgroup: from IGHV bias and AID activation to altered T-cell profiles
Marcelo Navarrete
Favorite
Navarro, Almudena

University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC)
1212 - High-dimensional profiling of CLL and T cell interactions during early phase of disease using a 42-color full-spectrum cytometry panel
Almudena Navarro
Favorite
1503 - Analysis of resistance-related mutations in patients with Chronic Lymphocytic Leukemia treated with BTK or BCL2 inhibitors suggests different underlying resistance mechanisms and subclonal dynamics
Almudena Navarro
Favorite
1905 - Academic CD19-directed CAR-T ARI-0001 (varnimcabtagene autoleucel) for patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation
Almudena Navarro
Favorite
Navarro, Sergio

Hospital Clinic de Barcelona
1905 - Academic CD19-directed CAR-T ARI-0001 (varnimcabtagene autoleucel) for patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation
Sergio Navarro
Favorite
Navarro, Victor

Vall d'Hebron Institute of Oncology (VHIO)
1019 - Immunological Landscape of CLL Development and Response to Early BTK Inhibition in del(13q14) Mice
Victor Navarro
Favorite
Navrkalová, Veronika

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
1007 - Clonality assessment in multiclonal chronic lymphocytic leukemia using Sanger and next-generation sequencing approaches
Veronika Navrkalová
Favorite
Navrkalova, Veronika

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
1114 - Clonal shifts of TP53 mutations in patients treated with BTK and BCL2 inhibitors: analysis of accompanying genomic changes
Veronika Navrkalova
Favorite
Nawabi, Mohammad Reshad

Università del Piemonte Orientale
1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Mohammad Reshad Nawabi
Favorite
1227 - Clinical and Biological Impact of Plasma Cytokine Levels in Newly Diagnosed Chronic Lymphocytic Leukemia
Mohammad Reshad Nawabi
Favorite
Naylor-Adamson, Leigh

Hull York Medical School
1226 - Ibrutinib enhances the bias of T-cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia
Leigh Naylor-Adamson
Favorite
Neuenburg, Jutta K.

AbbVie Inc.
1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study
Jutta K. Neuenburg
Favorite
Neupane, Binod

Evidera
1505 - A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B-Cell Lymphomas
Binod Neupane
Favorite
Newton, Darren

University of Leeds
1437 - Effect of targeted treatment on IGHV subset #2 and #8 patients in CLL: Comparison of MRD defined Ibrutinib plus Venetoclax treatment to the Ibrutinib and FCR arms of the FLAIR Trial
Darren Newton
Favorite
Ng, Anita

Feinstein Institutes for Medical Research
1021 - Normal B Cells in MBL Show Abnormal Transcriptomic and Subset Distributions Compared to Healthy Donors: Evidence for Follicular Maturation in IGHV-Mutated MBL and Extrafollicular Maturation in IGHV-Unmutated MBL
Anita Ng
Favorite
1208 - Selectively targeting foreign antigen to surface membrane IgD leads to enhanced T-cell activation in patients with CLL and normal people
Anita Ng
Favorite
1305 - CLECL1⁺ Proliferative CLL Cells Remodel the Lymph Node Microenvironment Through Fibroblast Reprogramming, Th2 Polarization, and M2 Macrophage Induction to Promote Immune Evasion and Disease Progression
Anita Ng
Favorite
Nguyen Khac, Florence

APHP
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Florence Nguyen Khac
Favorite
Nguyen, Phuong-Hien

Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne Germany, Köln, Deutschland
1906 - Fibroblast mediated Modulation of bispecific Antibody Treatment in Chronic Lymphocytic Leukemia
Phuong-Hien Nguyen
Favorite
Nickl, Petr

CCP, Institute of Molecular Genetics of the Czech Academy of Sciences
1017 - Long Non-Coding RNA LINC00173 Regulates BCR Signaling Propensity and mRNA Translation via Ribonucleoprotein Granules in CLL Cells
Petr Nickl
Favorite
Nicolosi, Maura

Division of Hematology, A.O.U. CIttà della Salute e della Scienza di Torino
1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Maura Nicolosi
Favorite
1403 - Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
Maura Nicolosi
Favorite
Niemann, Carsten

Rigshospitalet, Copenhagen University Hospital
1407 - The impact of body mass index on overall survival in chronic lymphocytic leukemia
Carsten Niemann
Favorite
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Carsten Niemann
Favorite
1422 - Risk of Acute Kidney Injury and Cytopenias During Treatment of Chronic Lymphocytic Leukemia in a Nationwide Real-World Cohort
Carsten Niemann
Favorite
1438 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Carsten Niemann
Favorite
1441 - A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
Carsten Niemann
Favorite
1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Carsten Niemann
Favorite
Nierychlewska, Paulina Maria

Onco-hematology Division, European Institute of Oncology (IEO) IRCCS, Milan
1602 - Venetoclax in combination with chemotherapy in Richter Syndrome patients: a real-life experience
Paulina Maria Nierychlewska
Favorite
Nikitin, Eugene

Department of Hematology, Oncology, and Chemotherapy S. P. Botkin's City Hospital Moscow Russia
1438 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Eugene Nikitin
Favorite
Nilsson-Takeuchi, Anna

University of Southampton
1121 - High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.
Anna Nilsson-Takeuchi
Favorite
Nimir, Mohammed

University of Birmingham
1216 - BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.
Mohammed Nimir
Favorite
Nixon, Colin

Cancer Research UK-Scotland Institute
1206 - Subversion of ERK-MAPK-mediated mRNA translation elongation as a therapeutic strategy in CLL
Colin Nixon
Favorite
Nizetic Govic, Mia

University Hospital Dubrava
1529 - Prevalence of BTK, PLCG2, and BCL2 mutations in CLL patients in Croatia - KROHEM study
Mia Nizetic Govic
Favorite
Nomdedéu, Josep

Hospital de la Santa Creu i Sant Pau
1430 - Assessing measurable residual disease (MRD) by cell-free DNA (cfDNA): results from a real-world series
Josep Nomdedéu
Favorite
Norris, Kevin

Cardiff University
1121 - High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.
Kevin Norris
Favorite
Noto, Alessandro

Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda
1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience
Alessandro Noto
Favorite
Novak, Jan

University Hospital Královské Vinohrady and Third Faculty of Medicine
1409 - Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study
Jan Novak
Favorite
Nowakowski, Grzegorz

Department of Hematology, Mayo Clinic
1601 - Central Nervous System Involvement in Patients with Richter Transformation
Grzegorz Nowakowski
Favorite
Nowak-Ozimek, Ewelina

Department of Molecular Diagnostics, Holy Cross Cancer Centre, Kielce, Poland
LB05 - Integrated immunogenetic and cytogenetic profiling reveals distinct biological patterns among stereotyped BCR subsets in CLL
Ewelina Nowak-Ozimek
Favorite
Nuli, Maria

Department of Nursing, Mayo Clinic
1502 - Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi
Maria Nuli
Favorite
Nzunda, Collin

Muhimbili University of Health and Allied Sciences
1102 - Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania.
Collin Nzunda
Favorite